E-Chu Huang Selected Research

Zyflamend

2/2014	Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells.
1/2012	Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer.
11/2011	Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

E-Chu Huang Research Topics

Disease

3	Neoplasms (Cancer) 02/2014 - 11/2011
3	Prostatic Neoplasms (Prostate Cancer) 02/2014 - 11/2011

Drug/Important Bio-Agent (IBA)

3	ZyflamendIBA 02/2014 - 11/2011
2	Histone Deacetylases (Histone Deacetylase)IBA 02/2014 - 01/2012
2	Androgen Receptors (Androgen Receptor)IBA 01/2012 - 11/2011
1	EnzymesIBA 02/2014
1	Hormones (Hormone)IBA 01/2012
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2012
1	Biomarkers (Surrogate Marker)IBA 01/2012
1	AndrogensIBA 01/2012
1	Somatomedin Receptors (Somatomedin Receptor)IBA 11/2011

Therapy/Procedure

1	Therapeutics 01/2012